 Home > Biochemistry News > Biotechnology News > More than half of patients with psoriasis have almost completely eliminated skin symptoms. The first TYK2 inhibitor is about to come out?

More than half of patients with psoriasis have almost completely eliminated skin symptoms. The first TYK2 inhibitor is about to come out?

 Last Update: 2022-01-12
 Source: Internet
 Author: User

Tags

devrom side effects

als treatment options

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Bristol-Myers Squibb (BMS) announced that the US FDA has accepted a new drug application (NDA) for the potential "first-in-class" oral selective TYK2 inhibitor deucravacitinib, and the European Medicines Agency (EMA) has also accepted deucravacitinib.

Psoriasis, also known as psoriasis, is a widespread chronic systemic immune-mediated disease that affects at least 100 million people worldwide

TYK2 is a member of the JAK family and is an intracellular signal kinase that mediates the signal transduction of IL-23, IL-12 and type I interferon (IFN)

▲Deucravacitinib has a unique mechanism of action (picture source: Bristol-Myers Squibb official website)

This regulatory application is based on the positive results obtained from 2 key phase 3 clinical trials

Reference materials:

[1] Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by US Food and Drug Administration and Validated by European Medicines Agency.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.